**uniQure Secures Up to $175 Million in New Non-Dilutive Loan Facility** LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 - uniQure N.V. (Nasdaq: QURE), a leader in gene therapy, has announced the refinancing of its existing $50 million debt and has secured a new senior secured term loan facility of up to $175 million with Hercules Capital, Inc. $(HTGC)$. The agreement extends the term of the current $50 million debt from January 2027 to October 2030 and provides access to an additional $125 million, subject to regulatory, financial, and lender approval milestones. The facility consists of three tranches: a $50 million refinancing, an additional $100 million accessible upon meeting certain regulatory and financial milestones related to AMT-130 (its investigational Huntington's disease therapy), and a further $25 million available with Hercules' approval. The loan carries a floating interest rate starting at 9.70%, lower than the previous rate of 11.95%. uniQure's CFO Christian Klemt said the transaction enhances the company's financial flexibility as it prepares for a potential commercial launch of AMT-130 in the U.S., anticipated in 2026. Leerink Partners advised uniQure on the financing.